Volasertib
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Volasertib is a polo-like kinase (Plk) inhibitor being developed by Boehringer Ingelheim for the treatment of AML. By targeting Plk, the inhibiter can cause cell-cycle arrest and apoptosis.
Analyst Outlook
Volasertib is Boehringer Ingelheim’s Phase III candidate that is being developed to treat patients aged ≥65, who are ineligible for standard induction therapy. By targeting this difficult-to-treat population, volasertib is likely to see good uptake as it expands upon limited treatment options available for these patients. However, volasertib would compete with Synta Pharmaceuticals’ Phase III ganetespib, which is also targeting the same population. Phase II clinical data for volasertib are more promising than for ganetespib, and Boehringer Ingelheim is seeking to demonstrate volasertib’s efficacy in a large-scale Phase III clinical trial.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 volasertib : Acute myeloid leukemia
LIST OF FIGURES
6 Figure 1: Volasertib – SWOT analysis for AML
7 Figure 2: Datamonitor Healthcare’s drug assessment summary for volasertib in AML
8 Figure 3: Datamonitor Healthcare’s drug assessment summary for volasertib in AML
LIST OF TABLES
4 Table 1: Volasertib drug profile for acute myeloid leukemia
5 Table 2: Ongoing clinical trial development for volasertib in AML
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Breast Cancer Pulse Survey 
Sign up to the